1. Pace JL, Yang G. Glycopeptides: Update on an old successful antibiotic class. Biochem Pharmacol. Mart 2006;71(7):968-80.
2. Anstead GM, Owens AD. Recent advances in the treatment of infections due to resistant Staphylococcus aureus. Curr Opin Infect Dis. 2004;17(6):549-55.
3. Kahne D, Leimkuhler C, Lu W, Walsh C. Glycopeptide and Lipoglycopeptide Antibiotics. Chem Rev. 01 Şubat 2005;105(2):425-48.
4. Butler MS, Hansford KA, Blaskovich MAT, Halai R, Cooper MA. Glycopeptide antibiotics: Back to the future. J Antibiot (Tokyo). Eylül 2014;67(9):631-44.
5. Bennett JE, Dolin R, Blaser MJ, editörler. Mandell, Douglas, and Bennett’s principles and practice of infectious diseases. Ninth edition. Philadelphia, PA: Elsevier; 2020. 1 s.
6. Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC, Eliopoulos GM. Relationship of MIC and Bactericidal Activity to Efficacy of Vancomycin for Treatment of Methicillin-Re-
sistant Staphylococcus aureus Bacteremia. J Clin Microbiol. Haziran 2004;42(6):2398-402.
7. Tongsai S, Koomanachai P. The safety and efficacy of high versus low vancomycin trough levels in the treatment of patients with infections caused by methicillin-resistant Staphylococcus
aureus: a meta-analysis. BMC Res Notes. Aralık 2016;9(1):455.
8. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, vd. Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant
Staphylococcus aureus Infections in Adults and Children. Clin Infect Dis. 01 Şubat 2011;52(3):e18-55.
9. Van De Beek D, Cabellos C, Dzupova O, Esposito S, Klein M, Kloek AT, vd. ESCMID guideline: diagnosis and treatment of acute bacterial meningitis. Clin Microbiol Infect. Mayıs 2016;22:S37-
62.
10. Paul M, Borok S, Fraser A, Vidal L, Leibovici L. Empirical antibiotics against Gram-positive infections for febrile neutropenia: systematic review and meta-analysis of randomized controlled
trials. J Antimicrob Chemother. 01 Nisan 2005;55(4):436-44.
11. Turk Klinik Mikrobiyoloji ve Infeksiyon Hastaliklari Dernegi Infektif Endokardit ve Diger Kardiyovaskuler Infeksiyonlar Calisma Grubu Istanbul, Turkiye, Simsek-Yavuz S, Akar AR, Turk
Kalp ve Damar Cerrahisi Dernegi (Ankara Universitesi, Ankara Sehir Hastanesi, Dr. Siyami Ersek Gogus Kalp ve Damar Cerrahisi Egitim ve Arastirma Hastanesi), Istanbul, Turkiye, Aydogdu
S, Turk Kardiyoloji Dernegi (Ankara Sehir Hastanesi, Hacettepe Universitesi, Dokuz Eylul Universitesi), Istanbul, Turkiye, vd. Diagnosis, Treatment and Prevention of Infective Endocarditis:
Turkish Consensus Report. Klimik DergisiKlimik J. 20 Eylül 2019;32(Supp1):2-116.
12. Van Hal SJ, Lodise TP, Paterson DL. The Clinical Significance of Vancomycin Minimum Inhibitory Concentration in Staphylococcus aureus Infections: A Systematic Review and Meta-analy-
sis. Clin Infect Dis. 15 Mart 2012;54(6):755-71.
13. Rybak MJ, Le J, Lodise TP, Levine DP, Bradley JS, Liu C, vd. Executive Summary: Therapeutic Monitoring of Vancomycin for Serious Methicillin‐Resistant Staphylococcus aureus Infections:
A Revised Consensus Guideline and Review of the American Society of Health‐System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and
the Society of Infectious Diseases Pharmacists. Pharmacother J Hum Pharmacol Drug Ther. Nisan 2020;40(4):363-7.
14. Li G, Walker MJ, De Oliveira DMP. Vancomycin Resistance in Enterococcus and Staphylococcus aureus. Microorganisms. 21 Aralık 2022;11(1):24.
15. Brogden RN, Peters DH. Teicoplanin: A Reappraisal of its Antimicrobial Activity, Pharmacokinetic Properties and Therapeutic Efficacy. Drugs. Mayıs 1994;47(5):823-54.
16. Van Bambeke F, Van Laethem Y, Courvalin P, Tulkens PM. Glycopeptide Antibiotics: from Conventional Molecules to New Derivatives. Drugs. 2004;64(9):913-36.
17. Mattox J, Belliveau P, Durand C. Oritavancin: A Novel Lipoglycopeptide. Consult Pharm J Am Soc Consult Pharm. Şubat 2016;31(2):86-95.
18. Baiardi G, Cameran Caviglia M, Piras F, Sacco F, Prinapori R, Cristina ML, vd. The Clinical Efficacy of Multidose Oritavancin: A Systematic Review. Antibiotics. 29 Eylül 2023;12(10):1498.
19. Corey GR, Loutit J, Moeck G, Wikler M, Dudley MN, O’Riordan W, vd. Single Intravenous Dose of Oritavancin for Treatment of Acute Skin and Skin Structure Infections Caused by Gram-Po-
sitive Bacteria: Summary of Safety Analysis from the Phase 3 SOLO Studies. Antimicrob Agents Chemother. Nisan 2018;62(4):e01919-17.
20. Dimopoulou D, Mantadakis E, Koutserimpas C, Samonis G. A Narrative Review on the Role of Dalbavancin in the Treatment of Bone and Joint Infections. Antibiot Basel Switz. 28 Eylül
2023;12(10):1492.
21. Roberts KD, Sulaiman RM, Rybak MJ. Dalbavancin and Oritavancin: An Innovative Approach to the Treatment of Gram-Positive Infections. Pharmacotherapy. Ekim 2015;35(10):935-48.
22. Seltzer E, Dorr MB, Goldstein BP, Perry M, Dowell JA, Henkel T, vd. Once-Weekly Dalbavancin versus Standard-of-Care Antimicrobial Regimens for Treatment of Skin and Soft-Tissue
Infections. Clin Infect Dis. 15 Kasım 2003;37(10):1298-303.
23. Wenzler E, Rodvold KA. Telavancin: The Long and Winding Road From Discovery to Food and Drug Administration Approvals and Future Directions. Clin Infect Dis. 15 Eylül 2015;61(suppl
2):S38-47.
24. Saravolatz LD, Stein GE, Johnson LB. Telavancin: A Novel Lipoglycopeptide. Clin Infect Dis. 15 Aralık 2009;49(12):1908-14.
25. Polyzos KA, Mavros MN, Vardakas KZ, Makris MC, Rafailidis PI, Falagas ME. Efficacy and Safety of Telavancin in Clinical Trials: A Systematic Review and Meta-Analysis. Spellberg B, editör.
PLoS ONE. 16 Ağustos 2012;7(8):e41870.
26. Heidary M, Khosravi AD, Khoshnood S, Nasiri MJ, Soleimani S, Goudarzi M. Daptomycin. J Antimicrob Chemother. 01 Ocak 2018;73(1):1-11.
27. Silverman JA, Mortin LI, VanPraagh ADG, Li T, Alder J. Inhibition of Daptomycin by Pulmonary Surfactant: In Vitro Modeling and Clinical Impact. J Infect Dis. 15 Haziran 2005;191(12):2149-
52.
28. Moore CL, Osaki-Kiyan P, Haque NZ, Perri MB, Donabedian S, Zervos MJ. Daptomycin versus vancomycin for bloodstream infections due to methicillin-resistant Staphylococcus aureus with
a high vancomycin minimum inhibitory concentration: a case-control study. Clin Infect Dis Off Publ Infect Dis Soc Am. 01 Ocak 2012;54(1):51-8.
29. Mishra NN, Bayer AS, Moise PA, Yeaman MR, Sakoulas G. Reduced Susceptibility to Host-Defense Cationic Peptides and Daptomycin Coemerge in Methicillin-Resistant Staphylococcus
aureus From Daptomycin-Naive Bacteremic Patients. J Infect Dis. 15 Ekim 2012;206(8):1160-7.
30. Boucher HW, Sakoulas G. Perspectives on Daptomycin Resistance, with Emphasis on Resistance in Staphylococcus aureus. Clin Infect Dis. 01 Eylül 2007;45(5):601-8.
31. Davis SL, McKinnon PS, Hall LM, Delgado G, Rose W, Wilson RF, vd. Daptomycin versus Vancomycin for Complicated Skin and Skin Structure Infections: Clinical and Economic Outcomes.
Pharmacother J Hum Pharmacol Drug Ther. Aralık 2007;27(12):1611-8.
32. Jones TW, Jun AH, Michal JL, Olney WJ. High-Dose Daptomycin and Clinical Applications. Ann Pharmacother. Kasım 2021;55(11):1363-78.
33. Smith K, Perez A, Ramage G, Gemmell CG, Lang S. Comparison of biofilm-associated cell survival following in vitro exposure of meticillin-resistant Staphylococcus aureus biofilms to the
antibiotics clindamycin, daptomycin, linezolid, tigecycline and vancomycin. Int J Antimicrob Agents. Nisan 2009;33(4):374-8.
34. Seaton RA, Gonzalez-Ruiz A, Cleveland KO, Couch KA, Pathan R, Hamed K. Real-world daptomycin use across wide geographical regions: results from a pooled analysis of CORE and
EU-CORE. Ann Clin Microbiol Antimicrob. Aralık 2016;15(1):18.
35. Enoch DA, Bygott JM, Daly ML, Karas JA. Daptomycin. J Infect. Eylül 2007;55(3):205-13.
36. Hassett MR. Daptomycin-induced eosinophilic pneumonia. JAAPA Off J Am Acad Physician Assist. 01 Nisan 2024;37(4):1-4.
37. Delgado G, Neuhauser MM, Bearden DT, Danziger LH. Quinupristin-dalfopristin: an overview. Pharmacotherapy. Aralık 2000;20(12):1469-85.